Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats

Izumi Harukuni, Anish Bhardwaj, Richard J. Traystman, Barbara Crain, Edythe D. London, Jeffrey Kirsch

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The IV administration of the potent σ1-receptor ligand 4-phenyl-1-(4- phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 μmol · kg-1 · h-1) for 1, 2, 3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC- determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 ± 13 mm3; 10% ± 3% of ipsilateral hemisphere; P <0.05) (mean ± SEM) compared with that in corresponding 1- day control rats (124 ± 22 mm; 29% ± 5% of ipsilateral hemisphere; P <0.05) or 4-day control rats (112 ± 10 mm; 26% ± 2% of ipsilateral hemisphere; P <0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP- treated rats were not different compared with 1- and 4-day saline-treated controls. These data demonstrate that the σ1-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection. Implications: σ-Ligands decrease infarction size in various animal models when given after the onset of stroke. Prolonged treatment with a potent σ-ligand is associated with loss of therapeutic efficacy for this compound.

Original languageEnglish (US)
Pages (from-to)1299-1305
Number of pages7
JournalAnesthesia and Analgesia
Volume87
Issue number6
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Ischemia
Infarction
Ligands
Middle Cerebral Artery Infarction
Halothane
4-phenyl-1-(4-phenylbutyl)piperidine
Neuroprotection
Brain Ischemia
Cerebral Cortex
Reperfusion
Wistar Rats
Animal Models
Stroke
Staining and Labeling
Wounds and Injuries
triphenyltetrazolium

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats. / Harukuni, Izumi; Bhardwaj, Anish; Traystman, Richard J.; Crain, Barbara; London, Edythe D.; Kirsch, Jeffrey.

In: Anesthesia and Analgesia, Vol. 87, No. 6, 12.1998, p. 1299-1305.

Research output: Contribution to journalArticle

Harukuni, Izumi ; Bhardwaj, Anish ; Traystman, Richard J. ; Crain, Barbara ; London, Edythe D. ; Kirsch, Jeffrey. / Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats. In: Anesthesia and Analgesia. 1998 ; Vol. 87, No. 6. pp. 1299-1305.
@article{f6919d7f48bc45e4a34eb4e47c2d7a4e,
title = "Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats",
abstract = "The IV administration of the potent σ1-receptor ligand 4-phenyl-1-(4- phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 μmol · kg-1 · h-1) for 1, 2, 3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC- determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 ± 13 mm3; 10{\%} ± 3{\%} of ipsilateral hemisphere; P <0.05) (mean ± SEM) compared with that in corresponding 1- day control rats (124 ± 22 mm; 29{\%} ± 5{\%} of ipsilateral hemisphere; P <0.05) or 4-day control rats (112 ± 10 mm; 26{\%} ± 2{\%} of ipsilateral hemisphere; P <0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP- treated rats were not different compared with 1- and 4-day saline-treated controls. These data demonstrate that the σ1-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection. Implications: σ-Ligands decrease infarction size in various animal models when given after the onset of stroke. Prolonged treatment with a potent σ-ligand is associated with loss of therapeutic efficacy for this compound.",
author = "Izumi Harukuni and Anish Bhardwaj and Traystman, {Richard J.} and Barbara Crain and London, {Edythe D.} and Jeffrey Kirsch",
year = "1998",
month = "12",
language = "English (US)",
volume = "87",
pages = "1299--1305",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats

AU - Harukuni, Izumi

AU - Bhardwaj, Anish

AU - Traystman, Richard J.

AU - Crain, Barbara

AU - London, Edythe D.

AU - Kirsch, Jeffrey

PY - 1998/12

Y1 - 1998/12

N2 - The IV administration of the potent σ1-receptor ligand 4-phenyl-1-(4- phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 μmol · kg-1 · h-1) for 1, 2, 3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC- determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 ± 13 mm3; 10% ± 3% of ipsilateral hemisphere; P <0.05) (mean ± SEM) compared with that in corresponding 1- day control rats (124 ± 22 mm; 29% ± 5% of ipsilateral hemisphere; P <0.05) or 4-day control rats (112 ± 10 mm; 26% ± 2% of ipsilateral hemisphere; P <0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP- treated rats were not different compared with 1- and 4-day saline-treated controls. These data demonstrate that the σ1-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection. Implications: σ-Ligands decrease infarction size in various animal models when given after the onset of stroke. Prolonged treatment with a potent σ-ligand is associated with loss of therapeutic efficacy for this compound.

AB - The IV administration of the potent σ1-receptor ligand 4-phenyl-1-(4- phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 μmol · kg-1 · h-1) for 1, 2, 3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC- determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 ± 13 mm3; 10% ± 3% of ipsilateral hemisphere; P <0.05) (mean ± SEM) compared with that in corresponding 1- day control rats (124 ± 22 mm; 29% ± 5% of ipsilateral hemisphere; P <0.05) or 4-day control rats (112 ± 10 mm; 26% ± 2% of ipsilateral hemisphere; P <0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP- treated rats were not different compared with 1- and 4-day saline-treated controls. These data demonstrate that the σ1-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection. Implications: σ-Ligands decrease infarction size in various animal models when given after the onset of stroke. Prolonged treatment with a potent σ-ligand is associated with loss of therapeutic efficacy for this compound.

UR - http://www.scopus.com/inward/record.url?scp=0031768609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031768609&partnerID=8YFLogxK

M3 - Article

C2 - 9842816

AN - SCOPUS:0031768609

VL - 87

SP - 1299

EP - 1305

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -